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Abstract
Background: To date, only a small portion of the genetic variation for primary open-angle glaucoma (POAG), the major type
of glaucoma, has been elucidated.
Methods and Principal Findings: We examined our two data sets of the genome-wide association studies (GWAS) derived
from a total of 2,219 Japanese subjects. First, we performed a GWAS by analyzing 653,519 autosomal common single-
nucleotide polymorphisms (SNPs) in 833 POAG patients and 686 controls. As a result, five variants that passed the
Bonferroni correction were identified in CDKN2B-AS1 on chromosome 9p21.3, which was already reported to be a significant
locus in the Caucasian population. Moreover, we combined the data set with our previous GWAS data set derived from 411
POAG patients and 289 controls by the Mantel-Haenszel test, and all of the combined variants showed stronger association
with POAG (P,5.8610
210). We then subdivided the case groups into two subtypes based on the value of intraocular
pressure (IOP)—POAG with high IOP (high pressure glaucoma, HPG) and that with normal IOP (normal pressure glaucoma,
NPG)—and performed the GWAS using the two data sets, as the prevalence of NPG in Japanese is much higher than in
Caucasians. The results suggested that the variants from the same CDKN2B-AS1 locus were likely to be significant for NPG
patients.
Conclusions and Significance: In this study, we successfully identified POAG-associated variants in the CDKN2B-AS1 locus
using a Japanese population, i.e., variants originally reported as being associated with the Caucasian population. Although
we cannot rule out that the significance could be due to the differences in sample size between HPG and NPG, the variants
could be associated specifically with the vulnerability of the optic nerve to IOP, which is useful for investigating the etiology
of glaucoma.
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Introduction
Glaucoma is a neurodegenerative ocular disease and one of the
leading causes of irreversible blindness worldwide [1]. It is
characterized by the progressive loss of retinal ganglion cells and
optic nerve axons, resulting in visual field defects [2]. One of the
well-known major risk factors for glaucoma is elevated intraocular
pressure (IOP) [2]. Thus, the measurement of IOP is routinely
involved in the diagnosis of glaucoma. In fact, the IOP level has
been applied to subdivide the most common form of glaucoma,
primary open-angle glaucoma (POAG), into two subtypes [3]:
POAG with high ($22 mmHg) IOP (POAG/HPG, high pressure
glaucoma; hereafter referred to as ‘‘HPG’’) and with normal
(,22 mmHg) IOP (POAG/NPG, normal pressure glaucoma;
hereafter referred to as ‘‘NPG’’). Interestingly, ,92% of the
Japanese POAG patients are categorized into the NPG subtype
[4], whereas ,41% of Caucasian POAG patients are categorized
as NPG [5], thus showing a unique epidemiological distribution of
Japanese patients compared with other ethnic groups.
Aside from IOP measurements, the diagnosis of glaucoma is
commonly made by observing optic nerve degeneration and visual
field defects by means of fundus examinations and visual field tests,
respectively. In the case of HPG, early drug treatment to lower
IOP immediately following the onset of visual field damage has
been shown to be quite effective in slowing the irreversible
progression toward blindness [6,7]. In contrast, since NPG
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33389patients show normal IOP, they are often misdiagnosed.
Therefore, both fundus examinations of the optic nerve and
visual field tests are critical for the proper diagnosis of NPG
patients. However, due to the restriction of the healthcare
expenditure to include those examinations into a person’s regular
medical checkup, especially in the preclinical state of glaucoma, it
would be of great benefit if the risk of developing glaucoma could
be ascertained based on a simple blood test to assess the genetic
markers for the disease.
Since glaucoma shows familial aggregation and its prevalence
varies between individuals of different ethnicities, it has been
theorized that genetic factors play a significant role in the
pathogenesis of glaucoma [8,9]. Therefore, several institutions
are making profound efforts to discover single-nucleotide variants
for glaucoma by conducting a genome-wide association study
(GWAS) [10–14], and there are a few published reports of the
association of particular loci, such as the CAV1/CAV2 locus
(7q31.1) [13] and the TMCO1 or CDKN2B-AS1 loci (1q24.1 or
9p21.3, respectively) [14], with POAG using Caucasian subjects.
However, it appears that a controversy still exists as to determining
the authentic variants associating with POAG, even within the
same ethnicity of European descent [14,15]. We previously
reported a GWAS and the subsequent follow-up study focused
on the high-ranked variants identified in the initial population
using in total of 1,575 Japanese subjects [10]. We identified six
variants located in three loci, 1q43, 10p12.31, and 12q21.31, on
the chromosome which were modestly associated with POAG,
although the association results were not reproducible with a
different population of different ethnicities [13,16,17]. In that
previous study, we combined the patients from both HPG and
NPG subtypes as a single case group in order to increase the
statistical power [10]. Therefore, the genetic loci that were
identified are most likely to be components of the molecular
mechanism shared by both subtypes. Another Japanese group
performed a GWAS [12] and discovered variants in SRBD1 on
2p21 and ELOVL5 on 6p12.1 that were associated with NPG (in
that study, NPG was referred to as ‘‘normal tension glaucoma’’)
[18]. However, since the findings in that study were derived from a
single population, replication studies to support those findings still
need to be conducted.
In this present study, we examined two independent GWAS
data sets, and then performed a meta-analysis by combining the
data sets in order to discover authentic genetic markers for POAG,
HPG, or NPG. We succeeded in identifying some significant
variants in the CDKN2B-AS1 locus using a Japanese population, as
that locus has also been shown to be significantly associated with
POAG in Caucasians [14]. Moreover, the variants that passed the
Bonferroni correction seemed to be associated with POAG and
POAG/NPG, thus suggesting that the locus potentially affects the
NPG, rather than the HPG, subtype of POAG. Although we still
need to confirm our findings by use of a larger HPG cohort in
order to increase the statistical power, the variants identified in this
study could be associated specifically with the vulnerability of the
optic nerve to IOP, thus enabling us to investigate the etiology of
glaucoma.
Results
We first performed a GWAS in 833 POAG patients and 686
control subjects (hereafter referred to as ‘‘Present GWAS’’;
Figure 1A) who were selected and divided into case and control
groups based on our strict diagnosis criteria. After genotyping,
653,519 SNPs passed the quality controls and were used for the
association study (Figure 1A). In a quantile-quantile (Q-Q) plot
(Figure S1A), the genomic inflation factor (l) showed 1.021,
suggesting that the population substructure should not have any
substantial effects on the association analysis. Under these
conditions, we obtained 8 genome-wide significant SNPs (Table
S1) that passed the Bonferroni correction threshold (0.05/
653,519=7.65610
28), of which 5 SNPs were located in
CDKN2B-AS1 on chromosome 9p21.3 (Figure 2). A few SNPs
that showed modest to strong association were distributed across a
single linkage disequilibrium (LD) block located in the locus
(Figure S2). The remaining genome-wide significant SNPs
identified from different chromosomes turned out to be genotyping
errors due to the poor 2D clusters (Figure S3B–D).
Next, we updated the case and control groups of the previous
GWAS population [10] with the latest clinical information and
ended up with 411 POAG patients and 289 controls (hereafter
referred to as ‘‘Previous GWAS’’; Figure 1A). One SNP
(rs8181047) of 5 genome-wide significant SNPs in CDKN2B-AS1
identified from the Present GWAS was not able to be assessed in
the Previous GWAS because a DNA probe of that particular SNP
was not designed for the Affymetrix 500 K platform. Consequent-
ly, we combined the two sets of GWAS genotype data for the
remaining 4 SNPs by use of the Mantel-Haenszel test [19], and the
level of significance of all 4 SNPs increased from P,5.2610
29 to
P,5.8610
210 (Table 1). These 4 SNPs were highly correlated
with one another (r
2.0.98), and were considered to have a similar
effect for POAG based on the conditional analysis. These results
suggested that it was effective to combine the data since the
population stratification between the two data sets seemed to be
ignorable, which was also supported by the results of the
heterogeneity test. Moreover, we assessed the confounding effects
Figure 1. Study design. (A) We first performed the ‘‘Present GWAS’’
for POAG and identified the 9p21.3 locus. This result was confirmed by
the combined analysis with the ‘‘Previous GWAS’’. (B) We then
subdivided the POAG subjects into two subtypes, POAG/HPG and
POAG/NPG, and each group was analyzed by combining the two data
sets in order to investigate the differences of statistical significance in
the 9p21.3 locus.
doi:10.1371/journal.pone.0033389.g001
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found to be statistically significant (Table S2), thus suggesting that
the obtained association results were specific to the case-control
comparison. In addition, the two sets of GWAS data for 40 SNPs
surrounding the significant 4 SNPs in the 9p21.3 locus were also
combined and analyzed (Table S3, Table S4). Since these 44
SNPs, in total, were genotyped in both the Present and Previous
GWAS, and all of the SNPs passed the genotyping quality
controls, these SNPs should prove useful in providing a broader
overview of the significance of the locus. The results showed that
the significance of combined SNPs was generally high between
22.0–22.1 Mb (Figure 3A). Within the particular locus, there
seemed to be two distinct LD blocks; one in the side including
genome-wide significant SNPs (‘‘LD Block 1’’ in Figure 3D) and
one in the other side with modestly associated SNPs (‘‘LD Block 2’’
in Figure 3D).
Figure 2. Association results of the Present GWAS. (A) The SNPs with a strong association appeared to exist in a cluster on chromosome 9 (red
arrow). (B) The five significant SNPs that passed the Bonferroni correction threshold (horizontal dotted line) were identified in CDKN2B-AS1 on the
9p21 locus. SNP positions followed the NCBI Build 36 coordinates. The genetic recombination rates (cM/Mb) estimated by HapMap Project [31] in
Release 22 are indicated by the thin blue line.
doi:10.1371/journal.pone.0033389.g002
Table 1. Association results of genome-wide significant SNPs in the Present GWAS.
Previous GWAS Present GWAS Previous & Present Combined
SNP:risk allele Chr. Position Frequency
aP OR (95% CI) Frequency
aP OR (95% CI) P
b OR (95% CI) Het-P
c
rs523096:A 9 22,009,129 0.89/0.84 6.0610
23 1.56 (1.13–2.14) 0.89/0.82 3.8610
29 1.86 (1.51–2.29) 1.6610
210 1.76 (1.48–2.10) 0.42
rs518394:C 9 22,009,673 0.89/0.85 1.5610
22 1.49 (1.08–2.07) 0.89/0.82 5.2610
29 1.85 (1.50–2.28) 5.8610
210 1.74 (1.46–2.07) 0.34
rs564398:A 9 22,019,547 0.90/0.85 4.7610
23 1.58 (1.15–2.18) 0.90/0.82 4.6610
29 1.86 (1.51–2.29) 1.4610
210 1.77 (1.49–2.11) 0.47
rs7865618:A 9 22,021,005 0.90/0.85 6.3610
23 1.56 (1.13–2.14) 0.90/0.82 2.0610
29 1.88 (1.53–2.32) 9.0610
211 1.78 (1.50–2.12) 0.39
aRisk allele frequency in POAG/controls.
bP value of combined 2 GWAS results by Mantel-Haenszel test.
cP value of Cochran’s Q heterogeneity test between Previous and Present GWAS.
doi:10.1371/journal.pone.0033389.t001
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both the Present and Previous GWAS populations were divided
into two subtypes based on the clinical record of IOP
measurement: 1) POAG patients with HPG (IOP$22 mmHg)
and 2) those with NPG (i.e., patients who consistently showed an
IOP of less than 22 mmHg) [3]. The number of subjects in each
subtype was found to be 330 HPG and 503 NPG patients and
215 HPG and 196 NPG patients in the Present and Previous
GWAS, respectively (Figure 1B). When we performed the analysis
separately using the Present GWAS data set, the Q-Q plots of
HPG vs control and NPG vs control appeared to be quite different
from one another (Figure S1B, C). In particular, the HPG results
indicated non-deviated Q-Q plots (Figure S1B). In fact, although
none of the SNPs were genome-wide significant for HPG (Figure
S4A), we obtained 4 genome-wide significant SNPs that passed the
Bonferroni correction threshold for NPG (Table S1, Figure S4B).
As for NPG, the significance level of all 4 SNPs also increased
when the two data sets were combined (Figure 3C, Table S3,
Figure 3. Combined analysis of the Present and Previous GWAS data in 9p21.3 locus. Three graphs representing the results of the
association studies for POAG (A), HPG (B), and NPG (C) are shown in order from upper to lower, respectively. The results derived from the Present
GWAS alone or the two combined GWAS data sets are indicated by the purple or green line graph plots, respectively. The lowest plot (D) shows an LD
plot in the same region. All of the Present and Previous GWAS subject data was applied to draw the LD plot by Haploview v4.2. The color indicating
pairwise r
2 and LD block were lined by using the confidence interval (95%) of pairwise D9. Vertical dashed redline indicates the same region between
the upper graphs and LD Block 1 and 2 at the lowest.
doi:10.1371/journal.pone.0033389.g003
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Bonferroni threshold of significance in relation to HPG
(Figure 3B, Table S3, Table S4). Although the significance level
of SNPs residing in LD Block 2 showed slight differences among
the different subtypes, the level in LD Block 1 seemed to be
determining the difference of significance between the two
subtypes, thus suggesting that the variants on LD Block 1 are
closely associated with the susceptibility to glaucoma in the 9p21.3
locus (Figure 3D). Surprisingly, all of the significant SNPs from
NPG overlapped with those obtained from POAG (Table S1).
However, when we performed the heterogeneity test between the
HPG and NPG groups, the results were not significant (P=0.21–
0.25, Table S3), suggesting that the significant differences between
the two subtypes could be due to the small sample size of the HPG
group. Although we need to confirm the above results using a
larger HPG cohort, these results suggested that the significant
SNPs identified in CDKN2B-AS1 on the 9p21.3 locus probably
serve as genetic markers of glaucoma, which could be useful for
investigating the etiology of glaucoma with respect to the
vulnerability of the optic nerve to IOP.
Discussion
In this study, we successfully identified genetic markers in
CDKN2B-AS1 strongly associated with POAG and POAG/NPG,
but not with HPG, by analyzing two GWAS data sets using
independent study populations totaling 2,219 Japanese subjects.
For the case-control study of the Present GWAS, we excluded the
samples without hesitation that didn’t meet our strict quality
control (see Supporting Information S1). Since we succeeded in
excluding the samples possessing a fair amount of no-call or
missed-call genotype data, our more stringent filters certainly
improved the actual genotyping results for the association studies
performed later. Thus, we were able to obtain an increased level of
significance without any substructure effects of the two populations
based on the definite diagnosis when combining the genotyping
results of the Present and Previous GWAS data sets (Figure 3).
Using our polished data sets derived from distinct case and
control subjects (see Methods and Supporting Information S1), we
succeeded in identifying a cluster of genome-wide significant SNPs
associated with POAG in CDKN2B-AS1, a non-coding gene with
an unknown function, on chromosome 9p21.3 (Figure 2A, B).
Several variants in chromosome 9p21 have been found to be
associated with a variety of common diseases, and 9p21 was
initially identified as a locus for coronary artery disease (CAD)
[20–23] and type-2 diabetes [24–26]. However, little is known
about the biological meanings underlying the locus, as 9p21 is a
‘‘gene desert’’ locus and most of the variants identified were non-
coding. Recently, Harismendy et al. [27] reported that they have
identified 33 enhancers in 9p21, some of which being within
CDKN2B-AS1, and it turned out to be the second densest gene
desert for predicted enhancers, thus suggesting the regulatory role
of sequences residing within non-coding loci. They finally
determined a few adjacent, as well as distant (.45 kb), target
gene regions relevant to CAD biology physically interacting with
the enhancer by 3D-DSL (also known as ‘‘4C’’), a chromatin
conformation capture technology, in human vascular endothelial
cells. Overall, their study has provided an excellent example of a
solution to link the unknown meanings of statistical association to a
biological function. Since the POAG variants were also identified
in CDKN2B-AS1, the variants would probably affect the expression
level of the downstream genes CDKN2A and CDKN2B. In fact,
Burdon et al. reported up-regulated CDKN2A and CDKN2B
expression in response to the elevated IOP [14], suggesting the
involvement of the locus in molecular pathways leading to
glaucoma development. Moreover, the possibility that the variants
would also affect the distant unidentified target genes in the
context of the complex etiology of glaucoma, as well as the nature
of the identified locus [27], cannot be ruled out.
To date, several institutions have attempted to discover variants
for glaucoma by conducting a GWAS, and a few published studies
have reported the association of particular loci with POAG using
Caucasian subjects (Table S5). Thorleifsson et al. reported the
association of common variants near CAV1/CAV2 on 7q31.1 using
a population of European ancestry [13]. In contrast, Kuehn et al.
reported that they failed to replicate their results in a United States
cohort [15]. Moreover, meta-analysis of the association results
derived from several institutions of Northern Europe, including the
data from Thorleifsson et al. [13], identified a few new loci
associated with POAG, including the CDKN2B-AS1 locus on
9p21.3 [17]. Recently, the new loci at TMCO1 on 1q24.1 and
CDKN2B-AS1 were reported to be associated with Australian
populations [14]. Thus far, only the association of the CDKN2B-
AS1 locus was replicated, even within the same ethnicity of
European descent. Interestingly, Thorleifsson et al. also showed a
modest association with the CAV1/CAV2 locus using Chinese
subjects [13], although the allele frequency of the particular
variant in Asian subjects was quite low when compared with that
in Caucasians, suggesting etiological differences due to the genetic
background. In fact, according to the results of our Present GWAS
for POAG, we were unable to replicate the association with the
CAV1/CAV2 and TMCO1 loci (Figure S5F, G, Table S5).
Moreover, in the Present GWAS, we were unable to replicate
the association results of the 6 SNPs identified in the previous
study [10] (Table S5), even though the populations were of the
same ethnic background, thus suggesting that we still need to
discover authentic variants, irrespective of the difference in
ethnicities, to elucidate the complex etiology of glaucoma.
Consequently, it should be noted that the variants identified in
the CDKN2B-AS1 locus in this study using a Japanese population
seemed to be shared with the Caucasian subjects (Table S5), thus
showing that we have successfully obtained one of the authentic
variants for POAG that is not ethnicity related.
In this study, we also subdivided the POAG subjects into two
subtypes based on the IOP level measurements in an attempt to
discover subtype-specific variants, which would be useful for
investigating the different mechanism of each pathogenesis. Since
the clinical states of both subtypes overlap almost completely, they
are usually categorized as a single disease. However, as a unique
epidemiological distribution compared with other ethnic groups,
,92% of the Japanese POAG patients fall into the NPG category,
as determined by the Tajimi study [4], a robust epidemiology
study. In fact, another Japanese group performed a GWAS
focused on discovering NPG-specific variants [12]. They reported
that the SNPs in SRBD1 on 7q31.1 and ELOVL5 on 6p12.1 were
associated with NPG, although our group was unable to replicate
those results (Figure S5D, E). On the contrary, we obtained an
unexpected result that the variants associated with NPG were
completely identical to those associated with POAG in CDKN2B-
AS1 identified in this study (Table S1). In contrast, none of the
variants were significant for HPG (Figure 3B). Although we cannot
rule out that the significance could be due to the differences in
sample size between HPG and NPG cases according to the
heterogeneity test (P=0.21–0.25; Table S3), the results suggested
that the genetic loci identified are most likely components of the
molecular mechanism specific for NPG. It has been reported that
there are differences in vulnerability of the optic nerve to IOP
between HPG and NPG [18]. It has also been theorized that
CDKN2B-AS1 Variants Associated with Glaucoma
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Since the variants identified in this study seemed to be shared
among different ethnicities in functional aspects as well, the other
variants should be contributing to the unique epidemiology of
NPG in Japanese. By continuing to build upon the detailed
investigation, such as obtaining in-depth sequencing data of the
non-coding 9p21 locus, it might be possible to reveal not only the
molecular mechanism of glaucoma pathogenesis but also the
genetic diversity that resides within the locus among different
ethnic backgrounds.
Methods
Ethics statement
This study was approved by the Institutional Review Board of
Kyoto Prefectural University of Medicine and all procedures were
conducted in accordance with the Declaration of Helsinki. All
participants provided written informed consent after an explana-
tion of the nature and possible consequences of the study.
Case and control subjects for the Present GWAS
All participants were interviewed to determine their familial
history of glaucoma and other ocular or general diseases. A total of
2,126 Japanese participants, including POAG patients, healthy
volunteers, and patients with other ocular diseases, were recruited
between March 2005 and December 2010 at the University
Hospital of Kyoto Prefectural University of Medicine (Kyoto,
Japan) to give peripheral blood samples for this study. A third
person who was blind to both the blood sampling and genotyping
assigned an anonymous code to each blood sample. Genomic
DNA used for the genotyping experiments was isolated from the
blood, and Epstein-Barr virus (EBV)-transformed lymphocytes
were prepared from the remaining blood as previously described
[29] to serve as the future resource of genomic DNA. POAG
patients and controls suitable for this study were precisely selected
based on the strict diagnosis as previously described [10]. In
particular, subtype selection was performed by dividing POAG
into two categories according to peak IOP without treatment;
POAG/High Pressure Glaucoma (POAG/HPG, defined as
$22 mmHg) and POAG/Normal Pressure Glaucoma (POAG/
NPG) [3]. All of the diagnostic procedures, including case-control
selection and subtype classification, were performed by three
ophthalmologists (YI, MU, and KM) from a single institution. The
age and female/male ratio of all of the subjects used in the Present
and Previous GWAS are shown in Table S6. To examine the
possible confounding effects of age and gender, we assessed the
correlations between the values and the genotype data from
the case and control samples by one-way ANOVA or chi-square
test (Table S2).
SNP genotyping and quality control for the Present
GWAS
First, 906,600 SNPs were genotyped for 2,126 Japanese subjects
by Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa
Clara, CA) according to the manufacturer’s instructions. As for the
Present GWAS population, 839 POAG patients and 708 controls
were selected after performing the quality control (QC) as
described (Supporting Information S1). To exclude the potential
inclusion of genetically related subjects into the population,
identity-by-descent (IBD) estimates were performed for all possible
combinations by PLINK v1.07 (http://pngu.mgh.harvard.edu/
,purcell/plink/). In total, 6 POAG patients and 22 controls were
assumed to be in first-degree relationships or in relationships with
a few more-distant relatives, and were thus excluded from the
Present GWAS population. Finally, the Present GWAS population
ended up with 833 POAG patients, comprised of 330 HPG and
503 NPG patients, and 686 controls. Population stratification for
the present GWAS population was examined by principal
component analysis using EIGENSTRAT software v3.0 (http://
genepath.med.harvard.edu/,reich/Software.htm). As for the
reference genomic population, the four HapMap populations
(CEU, YRI, JPT, and CHB) were simultaneously applied to
EIGENSTRAT. The generated cluster plots indicated that our
POAG and control population was genetically clustered within the
JPT population, and there was no outlier sample (Figure S6). We
performed SNP quality control for the population on the
autosomal SNPs based on the following QC filters: (i) call rate
per SNPs in case and control samples $95%, (ii) minor allele
frequency (MAF) in case and control samples $1%, and (iii)
Hardy-Weinberg equilibrium (HWE) in control samples P$0.001.
Consequently, we analyzed the remaining 653,519 SNPs for the
Present GWAS population.
Population update for reanalyzing the Previous GWAS
Since 6 years had passed since the patients and healthy
volunteers who participated in our Previous GWAS [10] were first
recruited, we updated the case (n=418) and control (n=300)
groups based on the latest clinical information. In total, 7 samples
from the case group and 11 samples from the healthy control
group were removed. The population for the reanalysis finally
ended up with 411 POAG patients, comprised of 215 HPG and
196 NPG patients, and 289 controls. The Previous GWAS data
was obtained by GeneChipH Human Mapping 500 K Array
platform (Affymetrix) containing 500,568 SNPs. The quality
control for the reanalysis was performed by using the same QC
filters as used in the Present GWAS. Genotype data derived from
the particular locus for combining with the Present GWAS data
was extracted from these filtered SNPs.
Data management and statistical analysis
To manage and analyze all of the genotype data, we used our
in-house Genoika Server System (SASA Plus Co., Ltd., Fukuoka,
Japan), which was well improved from the system used in the
Previous GWAS [10,30] by the same system engineers. In
addition, to manage the Previous GWAS data effectively, the
Labo Server System (World Fusion Co., Ltd.) was used
simultaneously. The Genoika Server System comes with PLINK
v1.07 (http://pngu.mgh.harvard.edu/,purcell/plink/), the R
program v 2.9.2 and 2.10.1 (http://www.r-project.org/), EIGEN-
STRAT software v3.0 (http://genepath.med.harvard.edu/
,reich/Software.htm), and Haploview 4.2 (http://www.broad
institute.org/scientific-community/science/programs/medical-and-
population-genetics/haploview/haploview) built in, and all the
analyseswere performed by use ofthissystem.In addition, Microsoft
OfficeExcel 2003 (MicrosoftCorporation, Redmond,WA) wasused
for preparing the data sets and statistical analysis. The frequency of
alleles in the case and control samples was compared by use of the
basicalleletest.Theoddsratio(OR)andtheupperandlowerlimitof
the 95%confidenceinterval (CI)ofeach SNPwerecalculated for the
allele possessing a higher frequency in the case samples than in the
control samples. The HWE was evaluated by the chi-square test. Q-
Q plots were generated by ranking the observed values from
minimumtomaximumand plotting themagainsttheirexpectedchi-
square values using the ‘‘snpMatrix’’ package ver 1.14.6 in the R
program (http://www.r-project.org/). We applied the Mantel-
Haenszel test [19] to combine the data derived from the two data
sets in order to reduce potential negative effects arising from the
CDKN2B-AS1 Variants Associated with Glaucoma
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Supporting Information
Figure S1 Q-Q plots for the Present GWAS. Quantile-
quantile (Q-Q) plots for the Present GWAS of POAG (A), HPG
(B), and NPG (C) were generated by ranking the observed chi-
square values from minimum to maximum and plotting them
against their expected values. Genomic inflation factors (l) are also
shown. These plots were created using the R-package snpMatrix.
(PDF)
Figure S2 LD plots in the 9p21 locus. LD plots were
generated from the Present GWAS data. The SNPs applied to
these plots and the span of the region are the same as shown in
Figure 2B. Upper and lower plots indicate the value of pairwise D9
and r2, respectively. The positions of 5 SNPs, which passed the
Bonferroni correction threshold in the Present GWAS, are drawn
in vertical dashed lines. These LD plots were generated using
Haploview v4.2.
(PDF)
Figure S3 Genotyping error check. 2D-cluster plots for the
representative SNPs obtained from chromosome 9 (A), chromo-
some 1 (B), chromosome 5 (C), and chromosome 12 (D) that
showed genome-wide significance. These 2D cluster plots were
drawn by Genotyping Console 4.1 software (Affymetrix).
(PDF)
Figure S4 GWAS results of two subtypes. Association
results of the Present GWAS for the two subtypes of POAG, HPG
(A) and NPG (B). The horizontal dashed line in each plot indicates
the Bonferroni correction threshold for each study.
(PDF)
Figure S5 Evaluation of previously reported loci/genes.
Evaluation of the POAG-associated loci/genes reported previously
using our Present GWAS data. The genes located in the loci are as
the follows: (A) ZP4, (B) PLXDC2, (C) TMTC2, (D) SRBD1, (E)
ELOVL5, (F) CAV1/CAV2, and (G) TMCO1. Each locus was
evaluated by the results of POAG vs control, POAG/HPG vs
control, and POAG/NPG vs control. The plotted SNPs were
selected from QC filtered SNPs. Target genes are placed in the
center of the 500-kb spanned region. Plots are shown with
genomic annotation and HapMap LD (JPT+CHB) made by the
UCSC Genome Browser (Human Mar. 2006).
(PDF)
Figure S6 Population stratification analysis. Population
stratification analysis by EIGENSTRAT in the Present GWAS
data set. POAG samples separated with HPG and NPG groups
were applied. The version of HapMap reference data is release22
(Build36). Since Control, NPG, HPG, and HapMap JPT samples
were tightly overlapped, only the plots for NPG (yellow cross) are
visible.
(PDF)
Table S1 Genome-wide significant SNPs that passed the
Bonferroni correction threshold in the Present GWAS.
(PDF)
Table S2 Analysis of confounding effects of age and sex
for the candidate SNPs.
(PDF)
Table S3 Present GWAS results in 9p21.3 locus.
(PDF)
Table S4 Combined GWAS results in 9p21.3 locus.
(PDF)
Table S5 Association results of Present GWAS for
previously reported SNPs.
(PDF)
Table S6 Characteristics of the samples.
(PDF)
Supporting Information S1 Quality control for genotyp-
ing.
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